HCA Healthcare, Inc.

(New York Stock Exchange)
Back to all articles
Slightly Bullish +15

Mizuho Has Lowered Expectations for HCA Healthcare (NYSE:HCA) Stock ...

AI-generated analysis

πŸ“‰ Mizuho lowered its price objective for HCA Healthcare from $525.00 to $475.00 while maintaining an 'outperform' rating.

πŸ“‰ UBS Group reduced its price target from $635.00 to $579.00 and set a 'buy' rating for the company.

πŸ“‰ Wall Street Zen downgraded shares of HCA Healthcare from a 'buy' rating to a 'hold' rating in May.

πŸ“ˆ The company reported quarterly earnings of $7.59 per share, beating analyst estimates of $7.56.

πŸ“ˆ Revenue for the quarter reached $20.23 billion, representing an 8.7% increase compared to the previous year.

πŸ“Š Institutional investors own 62.73% of the company's outstanding stock.

πŸ“ˆ Sei Investments Co. grew its position in HCA Healthcare by 56.3% during the second quarter.

πŸ“‰ Barclays reduced its target price from $402.00 to $387.00 and set an 'equal weight' rating.

πŸ“Š The consensus average price target across analysts is currently set at $465.05.

Bullish Signals
  • HCA Healthcare reported quarterly earnings of $7.59 per share, which beat the consensus estimate of $7.56 by $0.03.
  • The company achieved a net margin of 8.77% and generated revenue of $20.23 billion for the quarter.
  • Quarterly revenue increased by 8.7% on a year-over-year basis, demonstrating continued top-line growth.
  • Sei Investments Co. significantly increased its stake by 56.3%, now owning shares worth over $52 million.
  • NewEdge Advisors LLC lifted its holdings by 11.9% in the first quarter, indicating continued institutional confidence.
Risk Factors
  • Mizuho lowered its price objective from $525.00 to $475.00, citing a potential upside of only 16.31% from current levels.
  • UBS Group reduced its price target from $635.00 to $579.00 in a recent research report.
  • Wall Street Zen downgraded the stock from a 'buy' rating to a 'hold' rating in May.
  • Barcls reduced its target price from $402.00 to $387.00 and assigned an 'equal weight' rating.
  • Weiss Ratings downgraded HCA Healthcare from a 'buy (b-)' rating to a 'hold (c+)' rating in June.
Full Analysis
Analyst sentiment regarding HCA Healthcare (NYSE:HCA) has turned mixed following a series of price target reductions from major firms including Mizuho, UBS Group, and Barclays. Despite these downgrades, the stock maintains an overall consensus rating of 'Moderate Buy' with an average price target of $465.05, according to MarketBeat data. The company recently reported strong quarterly financial results for the quarter ended July 24th, beating earnings estimates and showing robust revenue growth. HCA Healthcare posted $7.59 per share in earnings, surpassing the consensus of $7.56, while revenue reached $20.23 billion, an increase of 8.7% year-over-year. Institutional ownership remains significant at 62.73%, with notable activity from investors like Sei Investments Co., which increased its stake by over 56% in the second quarter. The firm continues to operate a large network of hospitals and healthcare facilities across the United States.